Prostate Cancer Diagnostic Market: Expected
Growth from $6.2 Billion in 2023 to $11.5 Billion by 2032 Amid
Rising Demand for Early Detection Technologies
Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to
discovering, developing, and deploying promising health
innovations, announced that its subsidiary, Pearsanta, Inc.
(“Pearsanta”), has submitted a grant application to the Prostate
Cancer Research Program (PCRP) under the Department of Defense
(DoD) Implementation Science Award funding mechanism seeking $2
million in funding. This non-dilutive funding initiative aims to
advance the early detection and management of prostate cancer, a
disease that remains one of the most prevalent and challenging
cancers affecting men globally.
The MPT™, a blood test detecting a specific 3.4 kb mitochondrial
DNA deletion, has shown robust diagnostic performance for
clinically significant prostate cancer. The proposed study aims to
first validate the MPT™ in its CLIA/CAP facility in Virginia. Once
the validation is completed, the Science Award, if granted, would
be expected to provide Pearsanta with sufficient funds to evaluate
the test in a randomized clinical trial (RCT) to determine its
effectiveness in better identifying men with PSA levels in the gray
zone who would have clinically significant prostate cancer and
potentially reducing unnecessary biopsies. Up to 1,000 men at risk
for prostate cancer based on PSA levels 2-10 ng/mL will be
randomized to “MPT-informed care” or standard of care and followed
for one year to determine the number and results of any performed
biopsies.
Prostate cancer is a significant health concern worldwide,
according to the World Health Organization (WHO), with an estimated
1.5 million new cases diagnosed globally in 2024, making it the
second most common cancer among men and the fourth most common
cancer overall. In the United States alone, approximately 299,010
new cases and around 35,250 deaths are expected this year,
according to the American Cancer Society. The lifetime risk for a
man being diagnosed with prostate cancer is about 1 in 8, while the
risk of dying from it is approximately 1 in 44.
Pearsanta’s Mitomic Technology Platform seeks to harness the
unique properties of mitochondrial DNA (mtDNA) to detect disease
through non-invasive, blood-based liquid biopsies. This platform is
designed to identify specific mutations in mtDNA indicative of
various diseases. Due to its high mutation rate and cell
persistence, mtDNA has the potential to be an excellent biomarker
for early disease detection. Currently, the program focuses on
developing tests for early cancer detection, ovarian, prostate, and
lung cancers, and addressing non-cancerous conditions like
endometriosis.
“Submitting this grant application to the Prostate Cancer
Research Program is a significant step in our ongoing mission to
revolutionize early disease detection,” said Christopher Mitton,
President of Pearsanta. “Prostate cancer remains one of the most
challenging cancers for men worldwide, highlighting the urgent need
for more accurate and non-invasive diagnostic tools. We believe
that securing this non-dilutive funding would allow us to
accelerate our efforts to demonstrate the test's clinical utility
and contribution to prostate cancer diagnostics. The MPT™ has the
potential to significantly improve clinical outcomes by reducing
unnecessary biopsies and enabling the early detection of prostate
cancers. As we advance the validation of the MPT™ for clinical use
and position it as a laboratory-developed test, we are confident
that this innovation, if successful, will transform prostate cancer
diagnostics and improve patient outcomes globally."
The DoD’s PCRP Implementation Science Award is a highly
competitive funding opportunity to accelerate the adoption of
evidence-based practices in prostate cancer care. Pearsanta's
application underscores its commitment to advancing healthcare
through innovative diagnostic solutions and reflects its ongoing
efforts to address some of the most pressing challenges in
healthcare.
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt,
commented, “Through the Aditxt platform, we are seeking to
accelerate Pearsanta’s path to commercialization, positioning it
for long-term success as it advances innovations in precision
health. This aligns with our broader strategy to accelerate each
subsidiary to achieve growth and make a significant impact. By
advancing these efforts, we aim to bring promising innovations to
market that address critical healthcare needs and improve patient
outcomes globally.”
Aditxt currently operates two programs focused on immune health
and precision health. The Company plans to introduce two additional
programs dedicated to public health and women’s health. For the
latter two programs, Aditxt has entered into an Arrangement
Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI;
OTCPink: APLIF), which focuses on infectious diseases, and a Merger
Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM),
which focuses on women’s health. Each program will be designed to
function autonomously while collectively advancing Aditxt’s mission
of discovering, developing, and deploying innovative health
solutions to tackle some of the most urgent health challenges. The
closing of each of the transactions with Appili and Evofem is
subject to several conditions, including but not limited to
approval of the transactions by the respective target shareholders
and Aditxt raising sufficient capital to fund its obligations at
closing. No assurance can be provided that all of the conditions to
closing will be obtained or satisfied or that either of the
transactions will ultimately close.
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to
discovering, developing, and deploying promising innovations.
Aditxt’s ecosystem of research institutions, industry partners, and
shareholders collaboratively drives their mission to “Make
Promising Innovations Possible Together.” The innovation platform
is the cornerstone of Aditxt’s strategy, where multiple disciplines
drive disruptive growth and address significant societal
challenges. Aditxt operates a unique model that democratizes
innovation, ensures every stakeholder’s voice is heard and valued
and empowers collective progress.
For more information, www.aditxt.com.
Follow us on:
Linkedin: https://www.linkedin.com/company/aditxt Facebook:
https://www.facebook.com/aditxtplatform/
About Pearsanta, Inc.
Pearsanta is a commercial-stage company dedicated to
revolutionizing precision diagnostics through advanced
technologies. Leveraging its proprietary Mitomic® Technology
Platform, Pearsanta focuses on early disease detection,
significantly improving patient outcomes. The company’s diagnostic
portfolio includes ovarian and prostate cancers and endometriosis
tests. By identifying specific mitochondrial DNA (mtDNA) mutations,
Pearsanta’s non-invasive, blood-based liquid biopsies provide rapid
and accurate disease detection. Committed to enhancing lifelong
well-being, Pearsanta addresses critical healthcare needs with
innovative solutions that empower individuals to achieve optimal
health.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses, or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute its strategic M&A
initiatives; the Company’s ability to obtain the necessary funding
and partner to commence clinical trials; the Company’s intellectual
property position; the Company’s ability to develop commercial
functions; expectations regarding product launch and revenue; the
Company’s results of operations, cash needs, spending, financial
condition, liquidity, prospects, growth, and strategies; the
Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in Aditxt’s most recent Annual Report
on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904120561/en/
Mary O’ Brien mobrien@aditxt.com (516) 753-9933
Aditxt (NASDAQ:ADTX)
過去 株価チャート
から 8 2024 まで 9 2024
Aditxt (NASDAQ:ADTX)
過去 株価チャート
から 9 2023 まで 9 2024
